Every recommendation traced to real evidence
AI-powered clinical decision support that grounds every integrative medicine recommendation in scored, verifiable clinical claims. Built for physicians who demand rigor.
- Top-3 Diagnostic Accuracy
- 91.7%
- Hammoud et al. 400-vignette benchmark
- Top-1 Accuracy
- 78.6%
- Correct diagnosis as #1 pick
- Across All Metrics
- #1
- Outperforms Avey, Ada, physicians
- Sources Per Case
- 47+
- PubMed, trials, clinical reviews
Built for clinical rigor
Not another chatbot. A structured clinical reasoning pipeline with full auditability.
Claim Knowledge Objects
Clinical literature is decomposed into scored, policy-tagged claims — not raw text chunks. Every claim has an evidence tier and quality score.
Diagnostic Reasoning
Multi-hypothesis differential diagnosis with ICD-10 specificity. 4–6 ranked hypotheses per case, each with supporting evidence chains.
Integrative Medicine Recommendations
Integrative medicine recommendations based on our proprietary knowledge base — dosing context, personalized contraindications, and regulatory status.
Safety Validation
Every recommendation passes clinical safety checks: drug interactions, allergies, contraindications, and regulatory flags before reaching you.
Knowledge Graph
Entities and relationships extracted across our entire knowledge corpus and applied to your own patient cases — clinical concepts connected across the integrative medicine domain.
Literature Search
Our proprietary medical knowledge base supplemented with real-time PubMed and clinical trial literature.
See the reasoning. Trust the result.
Every analysis shows its work. Here's a real evidence chain from a patient case — anonymized, shown exactly as the platform produced it.
Can this patient take tesamorelin? Will he benefit?
- Age
- 47
- Sex
- Male
- Focus
- Longevity / prevention
- Chart flag
- G6PD deficiency
A 47-year-old male is loaded from three uploaded documents. There is no active complaint — the goal is to optimize healthspan, function, and prevention rather than treat an illness. One chart flag carries forward: a known G6PD deficiency, surfaced as a medication/exposure risk rather than an allergy. Asymptomatic by report; history is patient-reported and not yet clinician-verified.
Before reasoning, the engine commits to an explicit plan. Every later step is traceable back to it.
- 1process_patient_data·Analyze demographics, symptoms, and medical history
- 2query_knowledge_base·Search clinical protocols and research for relevant evidence
- 3search_web·Search external medical literature for supplemental evidence
- 4diagnostic_reasoning·Generate diagnostic hypotheses and treatment recommendations
- 5clinical_validation·Validate safety, check contraindications, and assess confidence
- Known G6PD deficiency — oxidative-stress vulnerability requiring medication/food/chemical precautions and hemolysis monitoring.
- Lab pattern reported: low RBC/HGB/HCT with elevated MCV, consistent with macrocytic anemia (etiology not provided).
- Iron studies abnormality: elevated serum iron and ferritin — suggests iron loading / inflammation / hemolysis rather than simple iron deficiency.
- Asymptomatic, prevention-focused; no chronic-disease history reported, but history is patient-reported and not clinician-verified.
- No medication or supplement list available — clinically relevant given G6PD exposure risks and possible macrocytosis contributors.
- Macrocytic anemia: decreased RBC/HGB/HCT with increased MCV.
- Elevated iron and ferritin (iron-overload signal vs. acute-phase response / hemolysis recycling).
G6PD deficiency plus macrocytic anemia with elevated iron/ferritin raises a flag for red-cell stress or impaired erythropoiesis rather than simple iron deficiency. Macrocytosis also points to B12/folate deficiency, alcohol/liver effects, thyroid dysfunction, or marrow stress — clarifying the driver matters before any longevity intervention that could increase metabolic demand.
Can this patient take tesamorelin? Will he benefit?
15 retrievedThe first approach to differential diagnosis of thyroid disorders is the measurement of free T4 and TSH.
Diagnosis was verified if patients had sustained hypothyroidism three weeks or later and/or T4 substitution therapy was initiated.
Participants were randomized 1:1 to 1.0 mg/d of tesamorelin (GHRH) or placebo subcutaneously 30 minutes before bedtime for 20 weeks.
Peptide therapy shows clinical evidence for supporting healthspan, cognition, immune function, and tissue repair — with the consistent caveat that protocols belong under monitored clinical supervision with baseline labs.
Climbing the longevity pyramid: overview of evidence-driven approaches
Longevity medicine is an emerging, iterative discipline focusing on early detection, preventive measures, and personalized approaches.
Potential role of bioactive peptides in prevention and treatment
Bioactive peptides have demonstrated significant antihypertensive and lipid-lowering activity in clinical trials.
Peptides for Longevity: What the Evidence Actually Shows
Clinical supervision is what separates a protocol from a gamble — labs first, then a monitored, individualized protocol.
Low RBC/HGB/HCT with increased MCV plus elevated iron and ferritin is not typical of iron deficiency. Raises concern for B12/folate deficiency, alcohol-related marrow toxicity, hypothyroidism, liver disease, medication effect, myelodysplasia, or hemolysis. Despite “no symptoms,” this is a clinically significant incidental finding requiring workup before any GH-axis optimization.
- Patient labs (observational): macrocytosis with anemia and high iron/ferritin
- Mechanistic: ineffective erythropoiesis (e.g. B12/folate) can raise iron indices
Known G6PD deficiency raises risk of oxidative-triggered hemolysis; anemia is present though hemolysis markers were not provided. Reticulocytosis can artifactually raise MCV; high ferritin can reflect iron recycling post-hemolysis. Needs a hemolysis panel and reticulocyte count.
- Patient history: confirmed G6PD deficiency
- Mechanistic: oxidative stress → RBC membrane damage → hemolysis
Knowledge base emphasizes thyroid assessment as first-line (TSH + free T4) and notes risk of missed central hypothyroidism. Hypothyroidism can cause macrocytosis and the dyslipidemia/weight changes that often motivate “optimization” therapies.
- KB (evidence 86/100): first approach is TSH + free T4
- KB (evidence 82/100): bioactive-TSH concept for primary/central hypothyroidism
Macrocytosis and elevated ferritin can occur with alcohol use and liver disease. Lifestyle (alcohol) and LFTs were not provided — a common, high-yield cause to rule in or out.
- Mechanistic: alcohol/liver injury → macrocytosis + elevated ferritin
Less common at 47, but must be considered with unexplained macrocytic anemia, especially if persistent or with other cytopenias. If anemia persists after nutritional/endocrine/liver/hemolysis causes are excluded, hematology evaluation is indicated.
- Observational: persistent unexplained macrocytosis warrants MDS evaluation
Tesamorelin raises endogenous pulsatile GH → IGF-1, but GH/IGF-1 activation can mask underlying drivers of fatigue/body composition and may be inappropriate with unrecognized disease. The biology to address first is the unexplained macrocytic anemia.
If hypothyroidism is present, replacing T4 normalizes thyroid signaling, improving erythropoiesis (may help macrocytosis), lipid metabolism, and energy — addressing a root driver that can mimic “low vitality.”
- This is an AI-generated analysis. Always consult a qualified healthcare professional.
- The primary issue is not “optimization” — an abnormal lab signal (macrocytic anemia with elevated iron/ferritin) requires evaluation before elective peptide protocols.
- Tesamorelin: the knowledge base contains no tesamorelin-specific safety/efficacy evidence for this case; any use would be off-label and should not proceed without full screening.
- G6PD deficiency: maintain strict avoidance of oxidative triggers and educate the patient on hemolysis warning signs; verify all supplements/OTCs.
Deferring tesamorelin is prudent: it is FDA-approved only for HIV-associated lipodystrophy and is otherwise off-label/investigational, can worsen glucose tolerance, and may unmask endocrine pathology — so anemia/macrocytosis and thyroid status should be clarified first. Levothyroxine is standard of care only with confirmed hypothyroidism. Monitor CBC with indices, B12/folate ± MMA/homocysteine, reticulocytes, and TSH/free T4.
From patient documents to clinical narrative
A structured pipeline, not a black box.
Upload Patient Documents
Upload lab results, intake forms, and clinical notes. The system extracts and populates the patient file automatically — no manual data entry.
Patient File Auto-Populated
Demographics, symptoms, labs, medications, and allergies structured automatically from uploaded documents. Review and refine as needed.
Ask a Clinical Question
Pose a question about the patient. The AI analyzes their data, retrieves evidence, reasons through differentials, and validates safety.
Review, Report & Act
Receive a physician-to-physician narrative with the full evidence trail. Download a professional, personalized medical report for your patient — every claim traceable. You make the final call.
Measured against the standard
400 peer-reviewed clinical vignettes. Same dataset. Direct comparison.
Top-1 Accuracy— Correct diagnosis as the #1 pick
Top-3 Accuracy— Correct diagnosis within the first 3 picks
Top-5 Accuracy— Correct diagnosis within the first 5 picks
Source: Hammoud et al. 2024 (JMIR AI), SymptomCheck Bench 2024. All systems evaluated on the identical 400 peer-reviewed clinical vignettes. See full methodology →
See it in action
Schedule a 30-minute demo and walk through a real clinical case with our team. No commitment, no sales pressure.